by Tony Akiwumi | Nov 8, 2025 | Pharma / Market Access
If you’ve ever sat in a cross-functional meeting, you’ll recognise the signs. Commercial wants bold claims. Regulatory insists on restraint. Medical clings to accuracy like a life raft. Market Access quietly sighs, repeating payer feedback that no one seems to want to...
by Tony Akiwumi | Nov 8, 2025 | Pharma / Market Access
Randomised controlled trials are tidy, logical, and beloved by regulators. But once a product leaves the pristine world of trial centres and meets real patients, the picture changes. Real-world evidence (RWE) decides whether a therapy’s promise holds up under pressure...
by Tony Akiwumi | Nov 5, 2025 | Pharma / Market Access
Pharma loves success stories. They fill conferences, case studies, and LinkedIn posts. Yet the most useful lessons often come from the launches that quietly underperformed — the ones no one wants to talk about. Having seen more than a few, I’ve noticed recurring...
by Tony Akiwumi | Nov 5, 2025 | Pharma / Market Access
Pricing strategies get plenty of attention in pharma. Teams hold workshops, hire consultants, and produce slide decks that look increasingly complex but say roughly the same thing. Yet, a pricing strategy on its own achieves little. Without genuine payer...
by Tony Akiwumi | Nov 5, 2025 | Pharma / Market Access
Market access is one of those phrases that looks perfect on a slide deck. It sounds strategic, sophisticated, and forward-thinking. Yet, when you look closely at underperforming launches, one pattern keeps repeating: access planning started too late. Everyone agrees...
